Home / Brand archive
105 reported ongoing
116 records in this archive. Latest source date Jul 23, 2026.
FDA enforcement status can lag behind the recall lifecycle. An empty search or a reported termination is not a personal product-safety determination.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.
Class IIReported ongoing
Distribution: Nationwide within the United States.
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Class IIReported ongoing
Distribution: USA Nationwide.
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
Class IIReported ongoing
Distribution: Nationwide within the United States
Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Class IIIReported ongoing
Distribution: Nationwide in the USA
Cross Contamination with Other Products
Class IIIReported ongoing
Distribution: U.S. Nationwide
CGMP Deviations: Market complaints received for gritty texture (grainy)
Class IIReported ongoing
Distribution: Nationwide within the United States
Failed Impurities/Degradation Specifications
Class IIReported ongoing
Distribution: US Nationwide.
Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution...
Class IIReported ongoing
Distribution: USA nationwide.
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
Class IIReported ongoing
Distribution: Nationwide within the USA
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
Class IIReported ongoing
Distribution: Nationwide within the USA
Failed Impurities/Degradation Specifications: Out of Specification (OOS) for related substances test for Anhydro Simvastatin at the 06-month time point during long-term stability study.
Class IIIReported ongoing
Distribution: Nationwide USA and PR
OOS results reported for the Dissolution (by UV) test.
Class IIReported ongoing
Distribution: Nationwide in the USA
CGMP Deviations
Class IIReported ongoing
Distribution: U.S. Nationwide
CGMP Deviations
Class IIReported ongoing
Distribution: U.S. Nationwide
CGMP Deviations
Class IIReported ongoing
Distribution: U.S. Nationwide
CGMP Deviations
Class IIReported ongoing
Distribution: U.S. Nationwide
CGMP Deviations
Class IIReported ongoing
Distribution: U.S. Nationwide
These examples come from this result page and are not a ranking of every recall reason.
This archive contains 116 records, including 105 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.